

Paolo Sportoletti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5091482/publications.pdf>

Version: 2024-02-01

109
papers

5,319
citations

185998

28
h-index

85405

71
g-index

110
all docs

110
docs citations

110
times ranked

8389
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>BRAF</i> Mutations in Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2011, 364, 2305-2315.	13.9	949
2	Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. <i>Blood</i> , 2011, 117, 3921-3928.	0.6	940
3	Identification of the <i>miR-106b</i> ~ <i>miR-25</i> MicroRNA Cluster as a Proto-Oncogenic <i>PTEN</i> -Targeting Intron That Cooperates with Its Host Gene <i>MCM7</i> in Transformation. <i>Science Signaling</i> , 2010, 3, ra29.	1.6	390
4	Mesenchymal cells recruit and regulate T regulatory cells. <i>Experimental Hematology</i> , 2008, 36, 309-318.	0.2	286
5	Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?. <i>Blood</i> , 2011, 117, 1109-1120.	0.6	210
6	Mutant NPM1 Maintains the Leukemic State through HOX Expression. <i>Cancer Cell</i> , 2018, 34, 499-512.e9.	7.7	209
7	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	3.3	198
8	NPM1-mutated acute myeloid leukemia: from bench to bedside. <i>Blood</i> , 2020, 136, 1707-1721.	0.6	152
9	Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. <i>Blood</i> , 2015, 125, 3455-3465.	0.6	124
10	Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. <i>Blood</i> , 2008, 111, 3859-3862.	0.6	120
11	<i>NOTCH1</i> PEST domain mutation is an adverse prognostic factor in $\text{B}\hat{\text{C}}\text{LL}$. <i>British Journal of Haematology</i> , 2010, 151, 404-406.	1.2	97
12	Mutational landscape of AML with normal cytogenetics: Biological and clinical implications. <i>Blood Reviews</i> , 2013, 27, 13-22.	2.8	95
13	Germline NPM1 mutations lead to altered rRNA 2 $\hat{\text{O}}$ -methylation and cause dyskeratosis congenita. <i>Nature Genetics</i> , 2019, 51, 1518-1529.	9.4	84
14	The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. <i>Blood</i> , 2010, 115, 3341-3345.	0.6	82
15	BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. <i>Blood</i> , 2015, 125, 1207-1216.	0.6	82
16	Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. <i>Current Opinion in Oncology</i> , 2009, 21, 573-581.	1.1	75
17	Notch1 modulates mesenchymal stem cells mediated regulatory T cell induction. <i>European Journal of Immunology</i> , 2013, 43, 182-187.	1.6	59
18	Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice. <i>Blood</i> , 2015, 126, 1790-1801.	0.6	58

#	ARTICLE	IF	CITATIONS
19	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	3.3	57
20	NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 229.	1.3	55
21	CD4 ⁺ CD25 ^{low} GITR ⁺ cells: A novel human CD4 ⁺ T cell population with regulatory activity. <i>European Journal of Immunology</i> , 2011, 41, 2269-2278.	1.6	54
22	Morgana/chp-1, a ROCK Inhibitor Involved in Centrosome Duplication and Tumorigenesis. <i>Developmental Cell</i> , 2010, 18, 486-495.	3.1	43
23	Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 459-466.	0.7	40
24	T regulatory cell separation for clinical application. <i>Transfusion and Apheresis Science</i> , 2012, 47, 213-216.	0.5	38
25	Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL. <i>Oncotarget</i> , 2015, 6, 16559-16572.	0.8	37
26	Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics. <i>British Journal of Haematology</i> , 2015, 170, 305-322.	1.2	36
27	Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2018, 143, 958-970.	2.3	32
28	Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML. <i>Blood</i> , 2021, 138, 2696-2701.	0.6	30
29	The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. <i>Blood</i> , 2013, 121, 3447-3458.	0.6	29
30	Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia. <i>Cell Chemical Biology</i> , 2020, 27, 678-697.e13.	2.5	27
31	Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML. <i>Leukemia</i> , 2021, 35, 2552-2562.	3.3	25
32	Clinical-Grade Expanded Regulatory T Cells Prevent Graft-versus-Host Disease While Allowing a Powerful T Cell-Dependent Graft-versus-Leukemia Effect in Murine Models. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1847-1851.	2.0	24
33	A Genetic Platform to Model Sarcomagenesis from Primary Adult Mesenchymal Stem Cells. <i>Cancer Discovery</i> , 2015, 5, 396-409.	7.7	22
34	The landscape of BRAF transcript and protein variants in human cancer. <i>Molecular Cancer</i> , 2017, 16, 85.	7.9	22
35	Wnt/Î²-Catenin Signaling Induces Integrin Î±4Î²1 in T Cells and Promotes a Progressive Neuroinflammatory Disease in Mice. <i>Journal of Immunology</i> , 2017, 199, 3031-3041.	0.4	22
36	IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation. <i>Cell Death and Disease</i> , 2018, 9, 1160.	2.7	22

#	ARTICLE	IF	CITATIONS
37	Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma. <i>Blood Cancer Discovery</i> , 2021, 2, 216-225.	2.6	22
38	NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells. <i>Frontiers in Oncology</i> , 2018, 8, 105.	1.3	20
39	Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 7540-7553.	3.2	20
40	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565.	1.2	20
41	NOTCH and NF- κ B interplay in chronic lymphocytic leukemia is independent of genetic lesion. <i>International Journal of Hematology</i> , 2013, 98, 153-157.	0.7	18
42	<i>BCOR</i> gene alterations in hematologic diseases. <i>Blood</i> , 2021, 138, 2455-2468.	0.6	18
43	Up-regulation of Translation Eukaryotic Initiation Factor 4E in Nucleophosmin 1 Haploinsufficient Cells Results in Changes in CCAAT Enhancer-binding Protein β Activity. <i>Journal of Biological Chemistry</i> , 2012, 287, 32728-32737.	1.6	17
44	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021, 35, 235-238.	3.3	17
45	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021, 13, 3240.	1.7	16
46	Glucocorticoid-Induced TNFR family Related gene (GITR) enhances dendritic cell activity. <i>Immunology Letters</i> , 2011, 135, 24-33.	1.1	15
47	Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2204-2210.	2.0	15
48	Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. <i>British Journal of Haematology</i> , 2019, 187, e8-e11.	1.2	14
49	Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL. <i>Cancers</i> , 2021, 13, 1280.	1.7	14
50	Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib?. <i>Blood Advances</i> , 2021, , .	2.5	14
51	Continuous treatment with Ibrutinib in 100 untreated patients with <i>TP53</i> disrupted chronic lymphocytic leukemia: A real-life campus CLL study. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	14
52	GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations. <i>Leukemia</i> , 2019, 33, 1827-1832.	3.3	13
53	Frontline treatment with the combination obinutuzumab \pm chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , 2020, 95, 604-611.	2.0	12
54	NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6665.	1.8	11

#	ARTICLE	IF	CITATIONS
55	NOTCH and Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 1825.	2.2	10
56	Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice. <i>Leukemia</i> , 2021, 35, 1949-1963.	3.3	10
57	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021, 96, E168-E171.	2.0	10
58	Interleukin-7-Engineered Mesenchymal Cells: In Vitro Effects on Naive T-Cell Population. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1250-1260.	2.0	9
59	Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2007, 48, 923-930.	0.6	9
60	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , 2021, 39, 570-574.	0.8	9
61	Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. <i>Blood</i> , 2021, 138, 2727-2730.	0.6	9
62	A novel NOTCH1 PEST domain mutation in a case of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1780-1782.	0.6	8
63	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	0.8	8
64	TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021, 96, E306-E310.	2.0	8
65	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. <i>Blood Cancer Journal</i> , 2020, 10, 92.	2.8	7
66	Interleukin 7-Engineered Stromal Cells: A New Approach for Hastening Naive T Cell Recruitment. <i>Human Gene Therapy</i> , 2005, 16, 752-764.	1.4	6
67	A scale of co-mutations in NPM1-driven AML. <i>Blood</i> , 2017, 130, 1877-1879.	0.6	6
68	Elucidating the Oncogenic Potential of NPMc+ In Vitro and In Vivo.. <i>Blood</i> , 2006, 108, 12-12.	0.6	6
69	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499.	1.1	5
70	The Role of Nucleophosmin In Hematopoietic Stem Cells and the Pathogenesis of Myelodysplastic Syndrome. <i>Blood</i> , 2010, 116, 95-95.	0.6	5
71	First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib. <i>Blood</i> , 2021, 138, 1474-1474.	0.6	5
72	Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	5

#	ARTICLE	IF	CITATIONS
73	How Does the NPM1 Mutant Induce Leukemia?. <i>Mental Illness</i> , 2011, 3, e6.	0.8	4
74	Ibrutinib Treatment of a Patient with Relapsing Chronic Lymphocytic Leukemia and Sustained Remission of Richter Syndrome. <i>Tumori</i> , 2017, 103, S37-S40.	0.6	4
75	NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status. <i>Frontiers in Oncology</i> , 2021, 11, 668573.	1.3	4
76	Identification and Characterization of Novel Rare Nucleophosmin (NPM1) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses. <i>Blood</i> , 2016, 128, 1717-1717.	0.6	4
77	Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 518-527.	0.8	4
78	Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo. <i>Cytotherapy</i> , 2009, 11, 86-96.	0.3	3
79	Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin. <i>Molecular Cytogenetics</i> , 2018, 11, 6.	0.4	3
80	Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab+bendamustine: Results of study on 486 cases outside clinical trials. <i>American Journal of Hematology</i> , 2021, 96, E269-E272.	2.0	3
81	Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021042.	0.5	3
82	A Curious Novel Combination of Nucleophosmin (NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML). <i>Genes</i> , 2021, 12, 1426.	1.0	3
83	Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax. <i>Blood</i> , 2020, 136, 25-26.	0.6	3
84	Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 332-340.	0.8	3
85	How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-4.	0.6	3
86	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. <i>Cancers</i> , 2022, 14, 207.	1.7	3
87	NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models. <i>Bone Marrow Transplantation</i> , 2021, 56, 2019-2023.	1.3	2
88	Richter's transformation in the heart. <i>Lancet Oncology</i> , The, 2021, 22, e341.	5.1	2
89	Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results. <i>Blood</i> , 2021, 138, 635-635.	0.6	2
90	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?. <i>Blood</i> , 2020, 136, 54-55.	0.6	2
92	The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein. <i>Leukemia</i> , 2022, , .	3.3	2
93	Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. <i>Blood Advances</i> , 2022, 6, 3875-3878.	2.5	2
94	Uncommon lymphoplasmacytic lymphoma with IgA paraproteinemia: a challenging clinical diagnosis solved by MYD88 mutation analysis. <i>Annals of Hematology</i> , 2019, 98, 1507-1508.	0.8	1
95	Abstract LB044: Tracking clonal hematopoiesis in patients with classical Hodgkin lymphoma. , 2021, , .		1
96	Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 729106.	1.3	1
97	Nucleophosmin Is Required for Macrophage Function and Maturation.. <i>Blood</i> , 2009, 114, 238-238.	0.6	1
98	Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) and Validation of a Proposed Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory (R/R) CLL Patients Receiving Idelalisib and Rituximab. <i>Blood</i> , 2019, 134, 5485-5485.	0.6	1
99	An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920). <i>Blood</i> , 2021, 138, 3746-3746.	0.6	1
100	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , 2020, 136, 47-49.	0.6	1
101	Mutations of the <i>Exportin 1 (XPO1)</i> Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. <i>Training/Validation Study</i> . <i>Blood</i> , 2020, 136, 31-32.	0.6	1
102	Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy. <i>Frontiers in Oncology</i> , 2021, 11, 638689.	1.3	0
103	Generation of a Factor Dependent Myeloid Cell Line from Nucleophosmin-1 Heterozygous (NPM-1+/âˆš) Mouse Bone Marrow as a Model for 5q- MDS. <i>Blood</i> , 2008, 112, 852-852.	0.6	0
104	Nucleophosmin-1 Interacts with CCAAT Enhancer Binding Protein Alpha (C/EBPÎ±) to Facilitate Granulocyte Maturation: Implications in MDS and AML.. <i>Blood</i> , 2009, 114, 2768-2768.	0.6	0
105	Upregulation of eIF4E in Nucleophosmin 1 (NPM1) Haploinsufficient Cells Alters CCAAT Enhancer Binding Protein Alpha (C/EBPÎ±) Activity: Implications for MDS and AML. <i>Blood</i> , 2011, 118, 2432-2432.	0.6	0
106	Targeting the Activating Mutations of NOTCH1 in T-Cell Lymphoblastic Leukemia with a New SERCA Inhibitor CAD204520. <i>Blood</i> , 2019, 134, 407-407.	0.6	0
107	External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study. <i>Blood</i> , 2019, 134, 4308-4308.	0.6	0
108	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020, 136, 23-25.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. <i>Blood</i> , 2020, 136, 30-31.	0.6	0